Eli Lilly (LLY) posted a blowout quarter, and Mad Cash says the GLP-1 drugmaker’s inventory story is way from over.
Jim Cramer and CNBC analyst Jeff Marks known as Eli Lilly and Nvidia prime momentum shares.
Why Eli Lilly’s GLP-1 Inventory Nonetheless Has Room to Run
The remark got here throughout a viewer query about how worth targets get set. Cramer raised Eli Lilly and Nvidia’s runs particularly when asking concerning the course of.
Marks, the CNBC Investing Membership’s portfolio analyst, stated shares like these want an extended time horizon than most.
“Shares like that you just additionally need to look out years out prematurely, too. Particularly within the case of Eli Lilly, the place it’s extra of in the direction of the tip of the last decade is the place it’s GLP-1 gross sales.”
— Jeff Marks, CNBC Investing Membership portfolio analyst, on Mad Cash
Eli Lilly’s second-quarter outcomes again that framing. Income hit $23 billion, up 48% 12 months over 12 months. A 60% soar in gross sales quantity offset a 13% drop in realized costs.
Administration raised full-year income steering to a spread of $85 billion to $87 billion. Mounjaro gross sales rose 91% to $9.9 billion worldwide. Zepbound’s U.S. income grew 44% to $4.9 billion.
Cramer’s different 2026 inventory picks lean on equally sturdy, multi-year themes slightly than short-term trades.
International GLP-1 Demand Is Nonetheless Early
Eli Lilly’s worldwide enterprise is rising even sooner than its U.S. enterprise. Income exterior the U.S. jumped 80% to $8.6 billion within the quarter, whereas quantity surged 113%.
That development got here whilst costs exterior the U.S. fell 36%. The decline adopted Mounjaro’s addition to China’s Nationwide Reimbursement Drug Checklist (NRDL), a program masking drug prices beneath public insurance coverage.
Decrease costs widen entry for thousands and thousands of latest sufferers, whilst they compress near-term margins. Morgan Stanley expects the worldwide weight problems and diabetes drug market to just about double by 2035.
The agency initiatives $190 billion in gross sales, up from $79 billion in 2025. Oral GLP-1 tablets and increasing insurance coverage protection are the primary drivers behind that forecast.
For Marks and Cramer, runway and scale are why Eli Lilly’s momentum appears to be like constructed for years, not quarters.
The put up Cramer’s Analyst Says Eli Lilly’s GLP-1 Inventory Rally Has Years Left to Run appeared first on BeInCrypto.